570 related articles for article (PubMed ID: 27645355)
1. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
Agahozo MC; Peferoen L; Baker D; Amor S
Mult Scler Relat Disord; 2016 Sep; 9():110-7. PubMed ID: 27645355
[TBL] [Abstract][Full Text] [Related]
2. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL
J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035
[TBL] [Abstract][Full Text] [Related]
3. B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model.
Jagessar SA; Heijmans N; Bauer J; Blezer EL; Laman JD; Hellings N; 't Hart BA
J Neuropathol Exp Neurol; 2012 Aug; 71(8):716-28. PubMed ID: 22805775
[TBL] [Abstract][Full Text] [Related]
4. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis.
Sefia E; Pryce G; Meier UC; Giovannoni G; Baker D
Mult Scler Relat Disord; 2017 May; 14():46-50. PubMed ID: 28619431
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135
[TBL] [Abstract][Full Text] [Related]
6. Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets.
Kap YS; van Driel N; Blezer E; Parren PW; Bleeker WK; Laman JD; Craigen JL; 't Hart BA
J Immunol; 2010 Oct; 185(7):3990-4003. PubMed ID: 20739677
[TBL] [Abstract][Full Text] [Related]
7. The role of antibodies in multiple sclerosis.
Weber MS; Hemmer B; Cepok S
Biochim Biophys Acta; 2011 Feb; 1812(2):239-45. PubMed ID: 20600871
[TBL] [Abstract][Full Text] [Related]
8. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
Kinzel S; Weber MS
CNS Drugs; 2016 Dec; 30(12):1137-1148. PubMed ID: 27844213
[TBL] [Abstract][Full Text] [Related]
9. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
Lee DH; Linker RA
Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461
[TBL] [Abstract][Full Text] [Related]
10. B cells in spontaneous autoimmune diseases of the central nervous system.
Berer K; Wekerle H; Krishnamoorthy G
Mol Immunol; 2011 Jun; 48(11):1332-7. PubMed ID: 21146219
[TBL] [Abstract][Full Text] [Related]
11. B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis.
Kap YS; Bauer J; Driel Nv; Bleeker WK; Parren PW; Kooi EJ; Geurts JJ; Laman JD; Craigen JL; Blezer E; 't Hart BA
J Neuropathol Exp Neurol; 2011 Nov; 70(11):992-1005. PubMed ID: 22002426
[TBL] [Abstract][Full Text] [Related]
12. CD20+ B cell depletion alters T cell homing.
Kap YS; van Driel N; Laman JD; Tak PP; 't Hart BA
J Immunol; 2014 May; 192(9):4242-53. PubMed ID: 24696233
[TBL] [Abstract][Full Text] [Related]
13. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
[TBL] [Abstract][Full Text] [Related]
14. T cell mediated pathogenesis in EAE: Molecular mechanisms.
Kurschus FC
Biomed J; 2015; 38(3):183-93. PubMed ID: 25900928
[TBL] [Abstract][Full Text] [Related]
15. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm.
Batoulis H; Addicks K; Kuerten S
Ann Anat; 2010 Aug; 192(4):179-93. PubMed ID: 20692821
[TBL] [Abstract][Full Text] [Related]
16. Single-cell profiling indicates a high similarity between immune cells in the cerebrospinal fluid and in meningeal ectopic lymphoid tissue in experimental autoimmune encephalomyelitis.
Georgieva T; Diddens J; Friedrich V; Lepennetier G; Brand RM; Lehmann-Horn K
Front Immunol; 2024; 15():1400641. PubMed ID: 38933267
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue.
Brand RM; Friedrich V; Diddens J; Pfaller M; Romana de Franchis F; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021057
[TBL] [Abstract][Full Text] [Related]
18. Paradox of B cell-targeted therapies.
Kurosaki T
J Clin Invest; 2008 Oct; 118(10):3260-3. PubMed ID: 18802484
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.
Lehmann-Horn K; Schleich E; Hertzenberg D; Hapfelmeier A; Kümpfel T; von Bubnoff N; Hohlfeld R; Berthele A; Hemmer B; Weber MS
J Neuroinflammation; 2011 Oct; 8():146. PubMed ID: 22027448
[TBL] [Abstract][Full Text] [Related]
20. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies.
Racke MK
Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S9-S18. PubMed ID: 18388801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
